vorinostat has been researched along with Parasitemia in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, MJ | 1 |
| Arnold, MS | 1 |
| Xu, W | 1 |
| Lancelot, J | 1 |
| Lamotte, S | 1 |
| Späth, GF | 1 |
| Prina, E | 1 |
| Pierce, RJ | 1 |
| Fairlie, DP | 1 |
| Skinner-Adams, TS | 1 |
| Andrews, KT | 1 |
1 other study available for vorinostat and Parasitemia
| Article | Year |
|---|---|
Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
Topics: Acetylation; Administration, Oral; Animals; Depsipeptides; HEK293 Cells; Histone Deacetylase Inhibit | 2017 |